Impact of the clinically approved BTK inhibitors on the conformation of full-length BTK and analysis of the development of BTK resistance mutations in chronic lymphocytic leukemia

Impact of the clinically approved BTK inhibitors on the conformation of full-length BTK and analysis of the development of BTK resistance mutations in chronic lymphocytic leukemia

Inhibition of Bruton’s tyrosine kinase (BTK) has proven to be highly effective in the treatment of B-cell malignancies such as chronic lymphocytic leukemia (CLL), autoimmune disorders, and multiple sclerosis. Since the approval of the first BTK inhibitor (BTKi), Ibrutinib, several other inhibitors i...

Full description

Bibliographic Details
Main Authors: Raji E Joseph, Thomas E Wales, Sandrine Jayne, Robert G Britton, D Bruce Fulton, John R Engen, Martin JS Dyer, Amy H Andreotti
Format: Article
Language:English
Published: eLife Sciences Publications Ltd 2024-12-01
Series:eLife
Subjects:
kinase inhibitor
allostery
resistance mutations
BTK
Bruton’s tyrosine kinase
CLL
Online Access:https://elifesciences.org/articles/95488

Internet

https://elifesciences.org/articles/95488

Similar Items